EFMC-ISMC 2021

XXVI EFMC International Symposium on Medicinal Chemistry

 Virtual Event    August 29-September 2, 2021

Programme

Indicated times are in CEST timezone.



Opening Ceremony

10:00

Opening Address by EFMC-ISMC 2021 Chairman

Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland

10:15

Opening Lecture
Title of talk to be confirmed

Dr Karin BRINER
NOVARTIS, Cambridge, United States

Award Ceremony Nauta

10:55

Award Ceremony Nauta presided by EFMC Past-President

Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland

11:05

THE NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
Award Lecture

Prof. Ad P. IJZERMAN
LEIDEN UNIVERSITY, Leiden, The Netherlands

11:45

Break

Award Ceremony UCB

13:10

THE UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
Award Lecture

Dr Malin LEMURELL
ASTRAZENECA, Gothenburg, Sweden

Award Ceremony Prous

14:00

THE PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Award Lecture

Prof. Gisbert SCHNEIDER
ETH ZÜRICH, Zürich, Switzerland

14:40

EFMC Fellows Ceremony

15:10

Closing

15:15

End of the Day

09:30

2nd Opening Lecture
Medicinal Chemistry: More than Ever

Dr Jean-Paul CLOZEL
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland

10:15

Start of sessions

Session 1 'Chemical Biology'

Molecular Imaging Tools for Chemical Biology


Session 2 'Technologies'

Novel Strategies and Methods for Drug Discovery and Development
(CPA Session)
Session 3 'Therapeutic Areas'

Breathing Life into Inhaled Drug Discovery: Challenges and Breakthroughs to the Clinic
(ACSMEDI Session)
Session 1 'Chemical Biology'

Molecular Imaging Tools for Chemical Biology


10:15
Session Chair
Dr Valle PALOMO
CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain
10:20
Chemical Biology of Antibody Conjugates and Natural Products
Prof. Gonçalo BERNARDES
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
11:00
Single-Molecule Imaging in Live Cells
Prof. Pablo RIVERA FUENTES
EPF LAUSANNE, Lausanne, Switzerland
11:20
Sensing Enzymatic Reactions with Quantum Dots
Dr Valle PALOMO
CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain
11:40
Oral Communication to be selected from submitted abstracts
Session 2 'Technologies'

Novel Strategies and Methods for Drug Discovery and Development
(CPA Session)
10:15
Session Chair
Prof. Ke DING
JINAN UNIVERSITY, Guangzhou, China
10:20
Allosteric Modulator Discovery: from Method Development to Applications
Prof. Jian ZHANG
SHANGHAI JIAO TONG UNIVERSITY, Shanghai, China
11:00
Title of talk to be confirmed
Prof. Cheng LUO
SHANGHAI INSTITUTE OF MATERIA MEDICA, Shanghai, China
11:20
Drug R&D Targeting Cell Necrosis
Prof. Shengyong YANG
SICHUAN UNIVERSITY, Sichuan, China
11:40
Oral Communication to be selected from submitted abstracts
Session 3 'Therapeutic Areas'

Breathing Life into Inhaled Drug Discovery: Challenges and Breakthroughs to the Clinic
(ACSMEDI Session)
10:15
Session Chair
Dr Nicole GOODWIN
GSK, King of Prussia, United States
10:20
Inhaled New Modalities in Respiratory Disease: Past, Present, Future
Dr Werngard CZECHTIZKY
ASTRAZENECA, Mölndal, Sweden
11:00
The Discovery of a Novel Inhaled PI3Kd Inhibitor by Lung Retention Optimisation
Ms Montse ERRA SOLA
ALMIRALL, S.A., Barcelona, Spain
11:20
The Design, Synthesis and Optimization of αvβ6 Antagonists as Potential Idiopathic Pulmonary Fibrosis Agents
Dr Niall ANDERSON
GLAXOSMITHKLINE, Hertfordshire, United Kingdom
11:40
Oral Communication to be selected from submitted abstracts
12:00

End of morning session

12:30

Company Workshops

13:15

Poster Session 1, Exhibition & Networking

15:30

Start of sessions

Session 4 'Chemical Biology'

Photochemistry in Drug Discovery: Photopharmacology, Phototoxicity and Synthesis
(ACSMEDI Session)
Session 5 'Technologies'

Cryo-EM as an Emerging Tool for Small-Molecule Drug Discovery


Session 6 'Therapeutic Areas'

Chemical Tools and Drug Discovery for Neuroinflammation
(EuChemS Session)

Session 4 'Chemical Biology'

Photochemistry in Drug Discovery: Photopharmacology, Phototoxicity and Synthesis
(ACSMEDI Session)
15:30
Session Chairs
Mr Timothy J. HENDERSON
MSD, Boston, United States
Dr Amjad ALI
MERCK & CO. INC., Kenilworth, United States
15:35
Photopharmacology: Towards Light-Controlled Therapy
Dr Wiktor SZYMANSKI
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
16:15
Understanding Immune Cell Interactions via Photocatalysis
Dr Niyi FADEYI
MERCK, Cambridge, United States
16:35
Oral Communication to be selected from submitted abstracts
17:05
Oral Communication to be selected from submitted abstracts
Session 5 'Technologies'

Cryo-EM as an Emerging Tool for Small-Molecule Drug Discovery


15:30
Session Chair
Dr Jean-Paul RENAUD
URANIA THERAPEUTICS, Ostwald, France
15:35
Speaker to be announced
16:15
Allosteric Regulation of GTP Cyclohydrolase I
Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany
16:35
The Role of Cryo-EM in Fragment-Based Drug Discovery
Dr Judith REEKS
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
17:05
Oral Communication to be selected from submitted abstracts
Session 6 'Therapeutic Areas'

Chemical Tools and Drug Discovery for Neuroinflammation
(EuChemS Session)

15:30
Session Chair
Dr Sonsoles MARTIN-SANTAMARIA
CIB-CSIC, Madrid, Spain
15:35
NLRP3 inflammasome inhibitors for Inflammatory and Neuroinflammatory Disease
Dr Alan WATT
NODTHERA, Little Chesterford, United Kingdom
16:15
Development of Fluorinated PET Tracers for Imaging of α1 Receptors in the Brain
Prof. Bernhard WÜNSCH
UNIVERSITY OF MÜNSTER, Münster, Germany
16:35
Oral Communication to be selected from submitted abstracts
17:05
Oral Communication to be selected from submitted abstracts
17:15

Start of sessions

Session 7.1.

First Time Disclosures (Part I)
Session 7.1.

First Time Disclosures (Part I)
Session Chair
17:15
Oral Communication to be selected from submitted abstracts
17:45
Oral Communication to be selected from submitted abstracts
18:15
Oral Communication to be selected from submitted abstracts
18:45

End of the Day

09:30

EFMC Prize Ceremony & Lectures 2020

09:35

The EFMC Prize for a Young Medicinal Chemist in Industry
Prize Lecture

09:55

The EFMC Prize for a Young Medicinal Chemist in Academia
Prize Lecture

10:15

Start of sessions

Session 8 'Chemical Biology'

Chemical Probes for Target Discovery and Validation

Session 9 'Technologies'

Innovative Synthesis for Medicinal Chemistry


Session 10 'Therapeutic Areas'

Addressing Neglected and Emerging Viral Diseases with Small Molecules
(AFMC Session)
Session 8 'Chemical Biology'

Chemical Probes for Target Discovery and Validation

10:15
Session Chair
Prof. Gyorgy KESERU
HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary
10:20
Chemical Probes to Explore Cancer Biology and Validate Drug Targets
Prof. Paul WORKMAN
INSTITUTE OF CANCER RESEARCH, London, United Kingdom
11:00
Chemical Probes to Study Lipid Signaling
Dr Mario VAN DER STELT
LEIDEN UNIVERSITY, Leiden, The Netherlands
11:20
Oral Communication to be selected from submitted abstracts
11:40
Oral Communication to be selected from submitted abstracts
Session 9 'Technologies'

Innovative Synthesis for Medicinal Chemistry


10:15
Session Chair
Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland
10:20
Recent Developments in Strategies and Tactics Towards Complex Secondary Metabolites
Prof. Erick M. CARREIRA
ETH ZÜRICH, Zürich, Switzerland
11:00
Innovative DNA-based Asymmetric Catalysis
Dr Stellios ARSENIYADIS
QUEEN MARY UNIVERSITY OF LONDON, London, United Kingdom
11:20
Scaffold-Assisted Peptide Cyclizations: Towards Protein Mimics
Prof. Jan VAN MAARSEVEEN
UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands
11:40
Oral Communication to be selected from submitted abstracts
Session 10 'Therapeutic Areas'

Addressing Neglected and Emerging Viral Diseases with Small Molecules
(AFMC Session)
10:15
Session Chair
Prof. Esin AKI-YALCIN
ANKARA UNIVERSITY, Ankara, Turkey
10:20
Discovery of a Novel Class of Small Molecule Dengue Virus Inhibitors
Dr Tim JONCKERS
JANSSEN, Beerse, Belgium
11:00
Antivirals Against Chikungunya Virus: Analyzing the Current Situation to Identify New Opportunities
Prof. Maria-Jesus PÉREZ-PÉREZ
INSTITUTO DE QUÍMICA MÉDICA, Madrid, Spain
11:20
Title of talk to be confirmed
Prof. Carolina H. ANDRADE
FEDERAL UNIVERSITY OF GOIAS , Goiânia, Brazil
11:40
Oral Communication to be selected from submitted abstracts
12:00

End of morning session

12:30

Company Workshops

13:15

Poster Session 2, Exhibition & Networking

15:30

Start of sessions

Session 11 'Chemical Biology'

Chemical Approaches to Stem Cell Differentiation
(ICBS Session)
Session 12 'Technologies'

Expanding Chemical Space through AI - Linking Synthesis Prediction and Automation

Session 13 'Therapeutic Areas'

New Strategies and Agents for Targeting Gram-Negative Pathogens

Session 11 'Chemical Biology'

Chemical Approaches to Stem Cell Differentiation
(ICBS Session)
15:30
Session Chair
Prof. Colin POUTON
MONASH UNIVERSITY, Clayton, Australia
15:35
A Chemical Approach to Controlling Cell Fate
Dr Sheng DING
UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States
16:15
Discovery of Small Molecules to Manipulate Cell Fate in vivo: Towards New Therapies for Degenerative Diseases
Prof. Angela RUSSELL
UNIVERSITY OF OXFORD, Oxford, United Kingdom
16:35
Oral Communication to be selected from submitted abstracts
16:55
Oral Communication to be selected from submitted abstracts
Session 12 'Technologies'

Expanding Chemical Space through AI - Linking Synthesis Prediction and Automation

15:30
Session Chair
Dr Ola ENGKVIST
ASTRAZENECA, Mölndal, Sweden
15:35
AI Assisted and Automated Chemical Synthesis
Prof. Klavs F. JENSEN
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States
16:15
Exploring Chemical Reactivity with an AI-Driven Chemputer
Prof. Leroy CRONIN
UNIVERSITY OF GLASGOW, Glasgow, United Kingdom
16:35
Oral Communication to be selected from submitted abstracts
16:55
Oral Communication to be selected from submitted abstracts
Session 13 'Therapeutic Areas'

New Strategies and Agents for Targeting Gram-Negative Pathogens

15:30
Session Chair
Dr Vicky STEADMAN
SAI LIFE SCIENCES LTD, Essex, United Kingdom
15:35
Therapies for Gram-Negative Bacterial Infections: New Approaches and Further Generations of Existing Series
Dr Mike DAWSON
MIKE DAWSON ANTIMICROBIAL RESEARCH CONSULTANCY LTD., Stevenage, United Kingdom
16:15
Tethered Peptide Macrocycles, a Novel Antibiotic Class Targeting Acinetobacter Baumannii
Dr Patrizio MATTEI
ROCHE INNOVATION CENTER BASEL, Basel, Switzerland
16:35
Oral Communication to be selected from submitted abstracts
16:55
Oral Communication to be selected from submitted abstracts
17:15

Start of sessions

Session 7.2.

First Time Disclosures (Part II)
Session 7.2.

First Time Disclosures (Part II)
17:15
Oral Communication to be selected from submitted abstracts
17:45
Oral Communication to be selected from submitted abstracts
18:15
Oral Communication to be selected from submitted abstracts
18:45

End of the Day

EFMC Prize Ceremony & Lectures 2021

09:35

The EFMC Prize for a Young Medicinal Chemist in Industry
Prize Lecture

09:55

The EFMC Prize for a Young Medicinal Chemist in Academia
Prize Lecture

10:15

Start of sessions

Session 14 'Chemical Biology'

Carbohydrate Recognition and Drug Design

Session 15 'Technologies'

Application of Artificial Intelligence in Drug Discovery Projects
Session 16 'Therapeutic Areas'

Tissue and Cell Specific Drug Delivery
(EUFEPS Session)
Session 14 'Chemical Biology'

Carbohydrate Recognition and Drug Design

10:15
Session Chair
Dr Alexander TITZ
HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL SCIENCES, Saarbrücken, Germany
10:20
C-type Lectin Receptors as Drug Targets
Dr Christoph RADEMACHER
UNIVERSITY OF VIENNA, Vienna, Austria
11:00
Design, Synthesis, and Development of Lectin Ligand Mimetics
Prof. Ulf NILSSON
LUND UNIVERSITY, Lund, Sweden
11:20
Lectins from Pathogens: From Structural Glycobiology to Antiadhesive Strategies
Dr Anne IMBERTY
CNRS/CERMAV, Grenoble, France
11:40
Oral Communication to be selected from submitted abstracts
Session 15 'Technologies'

Application of Artificial Intelligence in Drug Discovery Projects
10:15
Session Chair
Dr Christopher SWAIN
CAMBRIDGE MEDCHEM CONSULTING, Duxford, United Kingdom
10:20
Title of talk to be confirmed
Dr Hugo CEULEMANS
JANSSEN PHARMACEUTICA, Brussels, Belgium
11:00
Augmenting Drug Hunters with Generative Chemistry Models
Dr Nadine SCHNEIDER
NOVARTIS, Basel, Switzerland
11:20
Title of talk to be confirmed
Dr Gerhard HESSLER
SANOFI-AVENTIS DEUTSCHLAND, Frankfurt am Main, Germany
11:40
Oral Communication to be selected from submitted abstracts
Session 16 'Therapeutic Areas'

Tissue and Cell Specific Drug Delivery
(EUFEPS Session)
10:15
Session Chair
Prof. Sebastien PAPOT
SCT & UNIVERSITY OF POITIERS, Poitiers, France
10:20
Antibody-Drug Conjugates (ADCs) and Small Molecule-Drug Conjugates (SMDCs): a Direct Comparison
Prof. Dario NERI
ETH ZÜRICH, Zürich, Switzerland
11:00
Living in the World of RNA Therapeutics using Biomimetic Chemistry
Dr Mano MANOHARAN
ALNYLAM PHARMACEUTICALS, Cambridge, United States
11:20
Omics-Based Development of Nanomedicines for Safe and Effective Drug Delivery in Cancer
Prof. Erem BILENSOY
HACETTEPE UNIVERSITY, Ankara, Turkey
11:40
Oral Communication to be selected from submitted abstracts
12:00

End of morning sesssion

12:30

Company Workshops

13:15

Poster Session 3, Exhibition & Networking

15:30

Start of sessions

Session 17 'Chemical Biology'

Small Molecules Targeting RNA Function and Processing
Session 18

Emerging Topics

Session 19 'Therapeutic Areas'

Next Generation Drugs for Heart Failure

Session 17 'Chemical Biology'

Small Molecules Targeting RNA Function and Processing
15:30
Session Chair
Dr Maria DUCA
UNIVERSITY OF CÔTE D'AZUR, Nice, France
15:35
Drugging mRNA with Drug-like Small Molecules
Dr Jennifer PETTER
ARRAKIS THERAPEUTICS, Waltham, United States
16:15
Drugging RNA Modifying Enzymes
Dr David HARDICK
STORM THERAPEUTICS LTD, Cambridge, United Kingdom
16:35
Oral Communication to be selected from submitted abstracts
16:55
Oral Communication to be selected from submitted abstracts
Session 18

Emerging Topics

15:35
Oral Communication to be selected from submitted abstracts
15:55
Oral Communication to be selected from submitted abstracts
16:15
Oral Communication to be selected from submitted abstracts
16:35
Oral Communication to be selected from submitted abstracts
16:55
Oral Communication to be selected from submitted abstracts
Session 19 'Therapeutic Areas'

Next Generation Drugs for Heart Failure

15:30
Session Chair
Dr Alleyn T. PLOWRIGHT
WREN THERAPEUTICS LTD, Cambridge, United Kingdom
15:35
Identification of Potent and Long Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases
Dr Sergio MALLART
SANOFI R&D, CHILLY MAZARIN, France
16:15
Speaker to be confirmed
16:35
MAP4K4 Inhibitors for the Treatment of Myocardial Infarction
Dr Gary NEWTON
THE INSTITUTE OF CANCER RESEARCH, London , United Kingdom
16:55
Oral Communication to be selected from submitted abstracts
17:15

Plenary Lecture
Translational Chemistry

Prof. Phil BARAN
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States

18:00

End of the Day

09:30

Plenary Lecture
Targeting Protein Scaffolding Function in Kinases

Prof. Stefan KNAPP
GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany

10:15

Start of sessions

Session 20 'Chemical Biology'

Target Deconvolution Strategies in Drug Discovery
Session 21 'Technologies'

Prodrug Strategies in Drug Design and Discovery
Session 22 'Therapeutic Areas'

Targeting Fibrotic Diseases with Small Molecules
Session 20 'Chemical Biology'

Target Deconvolution Strategies in Drug Discovery
10:15
Session Chair
Prof. Paul BRENNAN
UNIVERSITY OF OXFORD, Oxford, United Kingdom
10:20
Title of talk to be confirmed
Dr Paola CASTALDI
LIFEMINE THERAPEUTICS, Cambridge, United States
11:00
Proteomes in 3D
Prof. Paola PICOTTI
ETH ZÜRICH, Zürich, Switzerland
11:20
Oral Communication to be selected from submitted abstracts
11:40
Oral Communication to be selected from submitted abstracts
Session 21 'Technologies'

Prodrug Strategies in Drug Design and Discovery
10:15
Session Chairs
Prof. Bernd CLEMENT
UNIVERSITY OF KIEL, Kiel, Germany
Prof. Jarkko RAUTIO
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
10:20
Prodrug Strategies in Medicinal Chemistry
Prof. Jarkko RAUTIO
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
11:00
New Examples for N-Hydroxyamidine Prodrugs
Prof. Bernd CLEMENT
UNIVERSITY OF KIEL, Kiel, Germany
11:20
Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist
Dr Daniel MEIBOM
BAYER PHARMA, Wuppertal, Germany
11:40
Oral Communication to be selected from submitted abstracts
Session 22 'Therapeutic Areas'

Targeting Fibrotic Diseases with Small Molecules
10:15
Session Chair
Dr Christian KUTTRUFF
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany
10:20
Novel Molecular Targets for the Treatment of Fibrosis
Prof. Joerg DISTLER
UNIVERSITY OF ERLANGEN–NUREMBERG, Erlangen, Germany
11:00
Discovery and Disclosure of GLPG1205, a First in Class GPR84 Negative Allosteric Modulator in Phase II Clinical Trial
Dr Romain GOSMINI
GALAPAGOS, Romainville, France
11:20
Oral Communication to be selected from submitted abstracts
11:40
Oral Communication to be selected from submitted abstracts
12:00

End of morning session

15:30

Start of sessions

Session 23

Late Breaking News

Session 24 'Technologies'

Biocatalysis & Late Stage Functionalisation

Session 25 'Therapeutic Areas'

Recent Advances in Anticancer Drug Discovery
Session 23

Late Breaking News

15:35
Oral Communication to be selected from submitted abstracts
15:55
Oral Communication to be selected from submitted abstracts
16:15
Oral Communication to be selected from submitted abstracts
16:35
Oral Communication to be selected from submitted abstracts
16:55
Oral Communication to be selected from submitted abstracts
Session 24 'Technologies'

Biocatalysis & Late Stage Functionalisation

15:30
Session Chair
Dr Radka SNAJDROVA
NOVARTIS PHARMA AG, Basel, Switzerland
15:35
Reprogramming Nonribosomal Biosynthesis
Prof. Donald HILVERT
ETH ZURICH, ZURICH, Switzerland
16:15
Bioorganic Synthesis – Adventures at the Chemistry/Biology Interface
Prof. Marko D. MIHOVILOVIC
TU WIEN, Vienna, Austria
16:35
Utilization of Fe/α-Ketoglutarate-Dependent Enzymes for C-H Functionalization
Prof. Rebecca BULLER
ZHAW SCHOOL OF LIFE SCIENCES AND FACILITY MANAGEMENT, Wädenswil, Switzerland
16:55
Oral Communication to be selected from submitted abstracts
Session 25 'Therapeutic Areas'

Recent Advances in Anticancer Drug Discovery
15:30
Session Chair
Prof. Roberto DI SANTO
SAPIENZA UNIVERSITY OF ROME, Rome, Italy
15:35
Targeting Cancer
Prof. Daniel RAUH
TU DORTMUND, Dortmund, Germany
Discovery of M3258, a Potent, Selective and Orally Efficacious Amino-Boronic Acid Based LMP7 Inhibitor for the Treatment of Multiple Myeloma
Dr Markus KLEIN
MERCK KGAA, Darmstadt, Germany
16:35
Magic in the Moonlight: Our Contribution to the Development of IDO1 Inhibitors for Cancer Immunotherapy
Prof. Tracey PIRALI
UNIVERSITÀ DEL PIEMONTE ORIENTALE, Novara, Italy
16:55
Oral Communication to be selected from submitted abstracts

Klaus Grohe Award Ceremony

17:25

THE KLAUS GROHE AWARD
Award Lecture

Prof. Stephan A. SIEBER
TECHNICAL UNIVERSITY MUNICH, Garching, Germany

18:05

Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2022